🎉 M&A multiples are live!
Check it out!

89bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for 89bio and similar public comparables like Pharming, Galapagos, and Benevolent AI.

89bio Overview

About 89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).


Founded

2019

HQ

United States of America
Employees

93

Website

89bio.com

Financials

Last FY Revenue n/a

LTM EBITDA -$361M

EV

$834M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

89bio Financials

89bio has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$361M.

In the most recent fiscal year, 89bio achieved revenue of n/a and an EBITDA of -$361M.

89bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See 89bio valuation multiples based on analyst estimates

89bio P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue n/a XXX n/a XXX XXX XXX
Gross Profit n/a XXX n/a XXX XXX XXX
Gross Margin n/a XXX n/a XXX XXX XXX
EBITDA -$361M XXX -$361M XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBIT -$365M XXX -$385M XXX XXX XXX
EBIT Margin n/a XXX n/a XXX XXX XXX
Net Profit -$346M XXX -$367M XXX XXX XXX
Net Margin n/a XXX n/a XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

89bio Stock Performance

As of May 30, 2025, 89bio's stock price is $10.

89bio has current market cap of $1.4B, and EV of $834M.

See 89bio trading valuation data

89bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$834M $1.4B XXX XXX XXX XXX $-2.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

89bio Valuation Multiples

As of May 30, 2025, 89bio has market cap of $1.4B and EV of $834M.

89bio's trades at n/a EV/Revenue multiple, and -2.3x EV/EBITDA.

Equity research analysts estimate 89bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

89bio has a P/E ratio of -4.1x.

See valuation multiples for 89bio and 12K+ public comps

89bio Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $1.4B XXX $1.4B XXX XXX XXX
EV (current) $834M XXX $834M XXX XXX XXX
EV/Revenue n/a XXX n/a XXX XXX XXX
EV/EBITDA -2.3x XXX -2.3x XXX XXX XXX
EV/EBIT -2.3x XXX -2.2x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -4.1x XXX -3.9x XXX XXX XXX
EV/FCF n/a XXX -2.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get 89bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

89bio Margins & Growth Rates

89bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $4.1M for the same period.

89bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

89bio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for 89bio and other 12K+ public comps

89bio Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth -5% XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX $4.1M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

89bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

89bio M&A and Investment Activity

89bio acquired  XXX companies to date.

Last acquisition by 89bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . 89bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by 89bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About 89bio

When was 89bio founded? 89bio was founded in 2019.
Where is 89bio headquartered? 89bio is headquartered in United States of America.
How many employees does 89bio have? As of today, 89bio has 93 employees.
Who is the CEO of 89bio? 89bio's CEO is Mr. Rohan Palekar.
Is 89bio publicy listed? Yes, 89bio is a public company listed on NAS.
What is the stock symbol of 89bio? 89bio trades under ETNB ticker.
When did 89bio go public? 89bio went public in 2019.
Who are competitors of 89bio? Similar companies to 89bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of 89bio? 89bio's current market cap is $1.4B
Is 89bio profitable? Yes, 89bio is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of 89bio? 89bio's last 12 months EBITDA is -$361M.
What is the current EV/EBITDA multiple of 89bio? Current EBITDA multiple of 89bio is -2.3x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.